204 related articles for article (PubMed ID: 32157421)
1. Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma.
Takeuchi M; Miyoshi H; Nakashima K; Kawamoto K; Yamada K; Yanagida E; Muta H; Moritsubo M; Umeno T; Suzuki T; Seto M; Ohshima K
Ann Hematol; 2020 May; 99(5):1093-1098. PubMed ID: 32157421
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.
Miyoshi H; Kiyasu J; Kato T; Yoshida N; Shimono J; Yokoyama S; Taniguchi H; Sasaki Y; Kurita D; Kawamoto K; Kato K; Imaizumi Y; Seto M; Ohshima K
Blood; 2016 Sep; 128(10):1374-81. PubMed ID: 27418641
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma.
Onishi A; Fuji S; Kitano S; Maeshima AM; Tajima K; Yamaguchi J; Kawashima I; Kawajiri A; Takemura T; Ito A; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Munakata W; Maruyama D; Tobinai K; Fukuda T
Ann Hematol; 2022 Apr; 101(4):799-810. PubMed ID: 35032188
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological analysis of immunohistochemical expression of immune checkpoint molecules in follicular lymphoma.
Yanagida E; Miyoshi H; Takeuchi M; Shimono J; Nakashima K; Yamada K; Kawamoto K; Moritsubo M; Shimasaki Y; Inoue K; Imamoto T; Furuta T; Kohno K; Ohshima K
Hematol Oncol; 2022 Oct; 40(4):530-540. PubMed ID: 35122292
[TBL] [Abstract][Full Text] [Related]
5. Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia/lymphoma.
Asano N; Miyoshi H; Kato T; Shimono J; Yoshida N; Kurita D; Sasaki Y; Kawamoto K; Ohshima K; Seto M
Histopathology; 2018 May; 72(6):945-954. PubMed ID: 29297942
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.
Kozako T; Yoshimitsu M; Fujiwara H; Masamoto I; Horai S; White Y; Akimoto M; Suzuki S; Matsushita K; Uozumi K; Tei C; Arima N
Leukemia; 2009 Feb; 23(2):375-82. PubMed ID: 18830259
[TBL] [Abstract][Full Text] [Related]
7. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma.
Chiba M; Shimono J; Suto K; Ishio T; Endo T; Goto H; Hasegawa H; Maeda M; Teshima T; Yang Y; Nakagawa M
Blood; 2024 Apr; 143(14):1379-1390. PubMed ID: 38142436
[TBL] [Abstract][Full Text] [Related]
8. An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.
Horlad H; Ma C; Yano H; Pan C; Ohnishi K; Fujiwara Y; Endo S; Kikukawa Y; Okuno Y; Matsuoka M; Takeya M; Komohara Y
Cancer Sci; 2016 Nov; 107(11):1696-1704. PubMed ID: 27564404
[TBL] [Abstract][Full Text] [Related]
9. [The microenvironment and immune status of peripheral T-cell lymphoma: focusing on AITL and ATLL].
Ohshima K; Miyoshi H; Yamada K
Rinsho Ketsueki; 2018; 59(5):574-587. PubMed ID: 29877249
[TBL] [Abstract][Full Text] [Related]
10. PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma.
Jalili-Nik M; Soltani A; Mashkani B; Rafatpanah H; Hashemy SI
Int Immunopharmacol; 2021 Sep; 98():107870. PubMed ID: 34153661
[TBL] [Abstract][Full Text] [Related]
11. Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study.
Skertich NJ; Chu F; Tarhoni IA; Szajek S; Borgia JA; Madonna MB
Surg Open Sci; 2021 Oct; 6():10-14. PubMed ID: 34386763
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance of CD28 overexpression in adult T-cell leukemia/lymphoma.
Sakamoto Y; Ishida T; Masaki A; Takeshita M; Iwasaki H; Yonekura K; Tashiro Y; Ito A; Kusumoto S; Iida S; Utsunomiya A; Ueda R; Inagaki H
Cancer Sci; 2022 Jan; 113(1):349-361. PubMed ID: 34738707
[TBL] [Abstract][Full Text] [Related]
13. TACC3 expression as a prognostic factor in aggressive types of adult T-cell leukemia/lymphoma patients.
Moritsubo M; Miyoshi H; Matsuda K; Yoshida N; Nakashima K; Yanagida E; Yamada K; Takeuchi M; Suzuki T; Muta H; Umeno T; Furuta T; Seto M; Ohshima K
Int J Lab Hematol; 2020 Dec; 42(6):842-848. PubMed ID: 32744749
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological analysis of immunohistochemical expression of CD47 and SIRPĪ± in adult T-cell leukemia/lymphoma.
Yanagida E; Miyoshi H; Takeuchi M; Yoshida N; Nakashima K; Yamada K; Umeno T; Shimasaki Y; Furuta T; Seto M; Ohshima K
Hematol Oncol; 2020 Dec; 38(5):680-688. PubMed ID: 32569413
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylated STAT3 expression predicts better prognosis in smoldering type of adult T-cell leukemia/lymphoma.
Morichika K; Karube K; Kayo H; Uchino S; Nishi Y; Nakachi S; Okamoto S; Morishima S; Ohshiro K; Nakazato I; Fukushima T; Masuzaki H
Cancer Sci; 2019 Sep; 110(9):2982-2991. PubMed ID: 31237072
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
[TBL] [Abstract][Full Text] [Related]
17. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma.
Shimauchi T; Kabashima K; Nakashima D; Sugita K; Yamada Y; Hino R; Tokura Y
Int J Cancer; 2007 Dec; 121(12):2585-90. PubMed ID: 17721918
[TBL] [Abstract][Full Text] [Related]
18. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.
He Y; Zhang X; Jia K; Dziadziuszko R; Zhao S; Deng J; Wang H; Hirsch FR; Zhou C
Transl Lung Cancer Res; 2019 Aug; 8(4):352-366. PubMed ID: 31555511
[TBL] [Abstract][Full Text] [Related]
19. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
20. OX40/OX40 ligand and its role in precision immune oncology.
Thapa B; Kato S; Nishizaki D; Miyashita H; Lee S; Nesline MK; Previs RA; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Metastasis Rev; 2024 Mar; ():. PubMed ID: 38526805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
